- Home
- EOSE vs VRDN Comparison
EOSE vs VRDN Comparison
Compare EOSE & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EOSE
- VRDN
- Stock Information
- Founded
- EOSE 2008
- VRDN 2006
- Country
- EOSE United States
- VRDN United States
- Employees
- EOSE N/A
- VRDN N/A
- Industry
- EOSE Industrial Machinery/Components
- VRDN Medical Specialities
- Sector
- EOSE Miscellaneous
- VRDN Health Care
- Exchange
- EOSE Nasdaq
- VRDN Nasdaq
- Market Cap
- EOSE 1.3B
- VRDN 1.3B
- IPO Year
- EOSE N/A
- VRDN N/A
- Fundamental
- Price
- EOSE $4.63
- VRDN $17.08
- Analyst Decision
- EOSE Strong Buy
- VRDN Strong Buy
- Analyst Count
- EOSE 3
- VRDN 11
- Target Price
- EOSE $22.83
- VRDN $38.50
- AVG Volume (30 Days)
- EOSE 13.2M
- VRDN 791.2K
- Earning Date
- EOSE 08-05-2025
- VRDN 08-07-2025
- Dividend Yield
- EOSE N/A
- VRDN N/A
- EPS Growth
- EOSE N/A
- VRDN N/A
- EPS
- EOSE N/A
- VRDN N/A
- Revenue
- EOSE $19,462,000.00
- VRDN $302,000.00
- Revenue This Year
- EOSE $945.82
- VRDN N/A
- Revenue Next Year
- EOSE $195.86
- VRDN $17,102.33
- P/E Ratio
- EOSE N/A
- VRDN N/A
- Revenue Growth
- EOSE 37.60
- VRDN 4.86
- 52 Week Low
- EOSE $1.40
- VRDN $9.90
- 52 Week High
- EOSE $7.36
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- EOSE 48.33
- VRDN 71.45
- Support Level
- EOSE $4.20
- VRDN $13.84
- Resistance Level
- EOSE $5.48
- VRDN $17.53
- Average True Range (ATR)
- EOSE 0.33
- VRDN 0.79
- MACD
- EOSE 0.04
- VRDN 0.22
- Stochastic Oscillator
- EOSE 34.62
- VRDN 87.80
About EOSE Eos Energy Enterprises Inc.
Eos Energy Enterprises Inc designs develop, manufactures, and markets zinc-based energy storage solutions for utility-scale, microgrid, and commercial & industrial (C&I) applications. The solutions are used in the utility sector, the renewable energy sector, and the industrial sector. It's flagship product Eos Znyth is a stationary battery energy storage system.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).